Clinical trials: sponsored by Amgen
ANCA-Associated Vasculitis
A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
The primary objective is to evaluate the efficacy of CCX168 (avacopan) to induce and sustain remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with…
- Trial name
- ADVOCATE (NCT02994927)
- Testing
- Avacopan, Prednisone, Cyclophosphamide
- Where
- 198 sites in United States, Australia and 18 more
- Volunteers
- 331 people
- Sponsor
- Amgen
Healthy Participants
Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants
The primary objective of this study is to evaluate the PK profile of AMG 510 alone and in combination with omeprazole in healthy participants.
- Trial name
- NCT05581992
- Testing
- AMG 510, Omeprazole
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Participants
A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy Participants
The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of AMG 510 alone and in combination with rifampin in healthy participants.
- Trial name
- NCT05577624
- Testing
- AMG 510, Rifampin
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Amgen
Hidradenitis Suppurativa, Acne Inversa
Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)
Phase 2 study of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa
- Trial name
- NCT03852472
- Testing
- Avacopan
- Where
- 91 sites in United States
- Volunteers
- 435 people
- Sponsor
- Amgen
Focal Segmental Glomerulosclerosis
A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome
An Open Label, Intra-Subject Dose Escalation Study of CCX140 B in Subjects with Primary FSGS and Nephrotic Syndrome
- Trial name
- NCT03703908
- Testing
- CCX140-B
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Amgen
Vasculitis
A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis
The aim of this trial is to optimize the treatment to induce remission for patients with non-life-threatening anti-neutrophil cytoplasmic antibody vasculitis (AAV).
- Trial name
- NCT01363388
- Testing
- CCX168
- Where
- 44 sites in Austria, Belgium and 8 more
- Volunteers
- 67 people
- Sponsor
- Amgen
ANCA-associated Vasculitis
Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis
The aim of this trial is to test the safety and efficacy of two dose regimens of the complement C5a receptor CCX168 in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
- Trial name
- NCT02222155
- Testing
- CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids, CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids
- Where
- 43 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Amgen
FSGS, Focal Segmental Glomerulosclerosis
A Study of CCX140-B in Subjects With FSGS
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with FSGS to be conducted in the North America, Europe and Australia
- Conditions
- FSGS, Focal Segmental Glomerulosclerosis, Glomerulosclerosis
- Trial name
- NCT03536754
- Testing
- CCX140-B
- Where
- 37 sites in United States, Australia and 6 more
- Volunteers
- 46 people
- Sponsor
- Amgen
Immunoglobulin A Nephropathy
Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade
The primary safety objective of this study is to evaluate the safety and tolerability of CCX168 in subjects with IgAN on background supportive therapy with a maximally tolerated dose of RAAS blockade.
- Trial name
- NCT02384317
- Testing
- CCX168
- Where
- 6 sites in United States, Sweden
- Volunteers
- 7 people
- Sponsor
- Amgen
C3 Glomerulopathy (C3G)
Controlled Trial Evaluating Avacopan in C3 Glomerulopathy
The aim of this trial is to evaluate the effect of avacopan treatment on renal disease activity in patients with complement component 3 glomerulopathy (C3G). Funding Source - FDA OOPD
- Trial name
- ACCOLADE (NCT03301467)
- Testing
- Avacopan
- Where
- 45 sites in United States, Belgium and 9 more
- Volunteers
- 57 people
- Sponsor
- Amgen
Small Cell Lung Cancer
Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer
The primary objective of the study is to provide expanded access to and characterize the safety profile of tarlatamab in participants with advanced small cell lung cancer (SCLC) after two or more prior lines of treatment…
- Trial name
- NCT06064500
- Testing
- Tarlatamab
- Where
- 23 sites in United States, Brazil and 2 more
- Sponsor
- Amgen
Rheumatoid Arthritis
Study to Evaluate Safety and Efficacy of CCX 354-C in Subjects With Rheumatoid Arthritis
The purpose of this study is to evaluate the safety and tolerability of multiple oral doses of CCX354-C at a number of dose levels in subjects with stable rheumatoid arthritis (RA).
- Trial name
- CARAT-1 (NCT01027728)
- Testing
- CCX 354-C
- Where
- 5 sites in Belgium, Romania
- Volunteers
- 24 people
- Sponsor
- Amgen
Rheumatoid Arthritis
A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy
This is a randomized, double-blind, placebo-controlled, Phase 2 study to evaluate the safety and efficacy of CCX354-C in subjects with rheumatoid arthritis partially responsive to methotrexate therapy.
- Trial name
- CARAT-2 (NCT01242917)
- Testing
- CCX-354-C, CCX354-C
- Where
- 41 sites in Belgium, Czechia and 6 more
- Volunteers
- 159 people
- Sponsor
- Amgen
Type 2 Diabetes Mellitus
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety and potential effectiveness of CCX140-B in subjects with Type 2 diabetes mellitus.
- Trial name
- NCT01028963
- Testing
- pioglitazone, CCX140-B
- Where
- 28 sites in Australia, Czechia and 3 more
- Volunteers
- 159 people
- Sponsor
- Amgen
Celiac Disease
A Phase II Study of CCX282-B in Patients With Celiac Disease
The purpose of this study is to determine whether CCX282-B is effective in mitigating the effects of gluten ingestion in patients with celiac disease
- Trial name
- NCT00540657
- Testing
- CCX282-B
- Where
- Finland
- Volunteers
- 90 people
- Sponsor
- Amgen
Crohn's Disease
A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease
The purpose of this study is to determine whether CCX282-B is effective in treating patients with moderate to severe Crohn's Disease.
- Trial name
- NCT00306215
- Testing
- CCX282-B
- Where
- 112 sites in Australia, Austria and 15 more
- Volunteers
- 436 people
- Sponsor
- Amgen
Crohn Disease
Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease
The purpose of this research study is to investigate the effects of an investigational medication, called CCX282-B, on safety and on the some of the symptoms of Crohn's Disease in patients who are experiencing an active flare-up…
- Trial name
- NCT00102921
- Testing
- CCX282-B
- Where
- 14 sites in United States
- Volunteers
- 70 people
- Sponsor
- Amgen
Healthy Volunteers
Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy Participants
The primary objectives of this study are to evaluate the effect of AMG 510 on the pharmacokinetics (PK) of metformin in healthy participants and to evaluate the effect of metformin on the PK of AMG 510 in healthy participants.
- Trial name
- NCT05550129
- Testing
- AMG 510, Metformin
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Participants
A Study to Assess the Effect of Food on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants
The primary objective of the study is to evaluate the PK of AMG 510 administered in the fasted and fed state in healthy participants.
- Trial name
- NCT05581758
- Testing
- AMG 510
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Participants
A Study to Evaluate the Drug-drug Interaction Effect of Itraconazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants
The primary objective of the study is to evaluate the pharmacokinetic (PK) profile of AMG 510 administered alone and in combination with itraconazole in healthy participants.
- Trial name
- NCT05568082
- Testing
- AMG 510, Itraconazole
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.